IPSEN S.A.S.

11 articles with IPSEN S.A.S.

• Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting

  8/25/2020

  Ipsen announced results from the MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva, to be presented during an oral presentation at the American Society for Bone and Mineral Research 2020 annual meeting.

• Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as a First-Line Combination Treatment for Metastatic Pancreatic Cancer

  6/17/2020

  Final analysis of the Phase 1/2 clinical study to be presented as a late-breaking virtual presentation at the ESMO World Congress on Gastrointestinal Cancer (WCGI) on July 1, 2020

• Photocure Enters into Final Agreement to Regain Worldwide Rights of Hexvix

  6/11/2020

  Reference is made to the OSE notification 27 April 2020 from Photocure ASA regarding the return of Hexvix® sales, marketing and distribution rights in Europe and other markets currently controlled by Ipsen Pharma SAS.

• Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy

  5/19/2020

  First published comparative data for key second-line (2L) advanced hepatocellular carcinoma (aHCC) treatments using a matching-adjusted indirect comparison (MAIC)

• Photocure Regains Worldwide Rights of Hexvix

  4/27/2020

  Ipsen achieved Hexvix 2019 sales of EUR 18.7 million and Photocure sees significant growth opportunities in Europe

• Ipsen Provides COVID-19 Update

  3/25/2020

  Ipsen (Euronext: IPN; ADR: IPSEY) provided today an update related to the impact of the Covid-19 pandemic on its global business which is affected in varying degrees in the countries impacted by the coronavirus, with very different and evolving situations from one country to another. Since the start of the health crisis, Ipsen has taken the necessary measures to ensure the safety of its employees around

• Clementia Pharmaceuticals Inc. obtains interim order for proposed transaction with Ipsen S.A. and enters into support and voting agreements with two additional significant shareholders

  3/7/2019

  Clementia Pharmaceuticals Inc. is pleased to announce that it has obtained an interim order from the Québec Superior Court in connection with the previously announced plan of arrangement pursuant to which a wholly-owned subsidiary of Ipsen S.A. is proposing to acquire all of the issued and outstanding common shares of Clementia for US$25.00 per share.

• Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma

  12/5/2018

  – Clinical trial will also explore single-agent activity of cabozantinib in the first-line setting –

• Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) Tablets for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib

  11/15/2018

  EC approval triggers $40 million milestone payment to Exelixis under Collaboration Agreement with Ipsen

• European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib

  11/15/2018

  Ipsen today announced that the European Commission (EC) has approved Cabometyx® (cabozantinib) 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.

• Ipsen to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15, 2018

  11/8/2018

  Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event